DiaSorin SpA
MIL:DIA

Watchlist Manager
DiaSorin SpA Logo
DiaSorin SpA
MIL:DIA
Watchlist
Price: 107.45 EUR 3.22% Market Closed
Market Cap: 5.7B EUR
Have any thoughts about
DiaSorin SpA?
Write Note

DiaSorin SpA
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

DiaSorin SpA
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
DiaSorin SpA
MIL:DIA
Capital Expenditures
-€131.3m
CAGR 3-Years
-13%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
El En SpA
MIL:ELN
Capital Expenditures
-€10.6m
CAGR 3-Years
3%
CAGR 5-Years
-46%
CAGR 10-Years
N/A
No Stocks Found

DiaSorin SpA
Glance View

Market Cap
5.7B EUR
Industry
Health Care

DiaSorin SpA is a prominent Italian diagnostic solutions provider that has carved a niche in the healthcare industry. Founded in 1968, the company specializes in developing and manufacturing innovative diagnostic tests that facilitate disease detection, monitoring, and prevention. With a robust portfolio that ranges from immunodiagnostics to molecular diagnostics, DiaSorin has made significant strides in addressing urgent healthcare needs. The company operates globally, serving hospitals and laboratories across numerous countries, and has established a strong commitment to research and development. This focus not only enhances their product offerings but also positions them as a key player in rapidly evolving sectors like infectious disease testing, oncology, and autoimmune disorders. For investors, DiaSorin presents an intriguing opportunity rooted in its strategic growth initiatives and resilience amid market challenges. The company's strong track record of revenue growth and profitability, coupled with its agile response to emerging health crises—such as the COVID-19 pandemic—highlights its operational efficiency and adaptability. Furthermore, with an ongoing emphasis on expanding its product lines and seeking partnerships to drive innovation, DiaSorin is well positioned to capitalize on the increasing demand for advanced diagnostic solutions. As healthcare continues to evolve with technological advances and personalized medicine, DiaSorin’s capabilities and strong market presence make it a compelling consideration for investors looking for sustainable growth in the life sciences sector.

DIA Intrinsic Value
92.61 EUR
Overvaluation 14%
Intrinsic Value
Price

See Also

What is DiaSorin SpA's Capital Expenditures?
Capital Expenditures
-131.3m EUR

Based on the financial report for Jun 30, 2024, DiaSorin SpA's Capital Expenditures amounts to -131.3m EUR.

What is DiaSorin SpA's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-11%

Over the last year, the Capital Expenditures growth was -25%. The average annual Capital Expenditures growth rates for DiaSorin SpA have been -13% over the past three years , -11% over the past five years .

Back to Top